Merck's Keytruda Loss In Liver Cancer Could Be Gain For Rivals
The drug demonstrates improvements in overall survival and progression-free survival, but not enough for success in KEYNOTE-240.
You may also be interested in...
The Swiss major focused almost exclusively on the benefits of the combination of Tecentriq and its TIGIT inhibitor tiragolumab at ASCO but also celebrated the approval of a Tecentriq/Avastin combo for hepatocellular carcinoma.
Full data at ESMO show Opdivo managed to scrape a tolerability edge over standard-of-care sorafenib in liver cancer, but eyes were drawn to Roche’s early study of Tecentriq/Avastin as the way forward in this difficult-to-treat cancer.
Top-line results from a Phase III study testing Opdivo versus Nexavar in first-line liver cancer fail to meet OS target. Bristol points to positive numerical trend, but the results are a setback in the indication.